Atlas Trials

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

Clinical trial NCT03609619 · COMPLETED

Trial details

NCT number
NCT03609619
Sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Attention Deficit Hyperactivity Disorder
Start date
2018-08-17
Primary completion
2018-11-23
Enrollment
109

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.